Is FibroGen Inc (FGEN) overvalued? · rev $29.6M
FibroGen Inc (FGEN) is a biotechnology company listed on NASDAQ.
This page asks whether FibroGen Inc (FGEN) looks expensive on cached numbers — not a short thesis.
Latest reported FGEN revenue for 2024-12-31 was $29.6M. Net income was -$47.6M. Revenue was down 36.7% from 2023-12-31 to 2024-12-31. FGEN currently screens at market cap $39.3M.
FGEN currently screens at market cap $39.3M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next FGEN 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the FGEN stock page for the full model, not this heading.
Not investment advice.